Belite Bio, Inc

NASDAQ:BLTE

Biotechnology

Healthcare
$156.23 +0.31%

+$0.46 today

Market cap
$6.29B
Beta
-1.24
P/E (TTM)
-65.9
EPS (TTM)
-$2.26
52W Low $56.10High $200.00

Volume 0.09M

Average 0.17M

BLTE Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Belite Bio, IncNASDAQ: BLTE

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit remains negative

Q3 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How BLTE compares with its peers on the latest reported figures

  • BLTE's LTM Sep 2026 gross profit of $0 is the 4th highest of the 6 companies compared; the peer median is $4.47M.
BLTE Competitors Peer median
Gross Profit for BLTE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRDOpus Genetics, Inc.LTM Mar 2026$5.95M +1.3%-29.1%49.6%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$5.83M -88.9%-4.0%76.5%
OCGNOcugen, Inc.LTM Mar 2026$4.47M -1.3%-6.6%100.0%
BLTEBelite Bio, IncLTM Sep 2026$0 ———
KODKodiak Sciences Inc.LTM Sep 2026$0 +100.0%——
KLRSKalaris Therapeutics IncLTM Mar 2026-$20K ———
Peer median (excluding BLTE) $4.47M+0.0%-6.6%76.5%

Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development7.42M8.87M24.84M29.94M45.38M
Selling, General & Admin2.38M3.95M6.82M10.06M38.83M
Operating Expenses9.8M12.82M31.67M40M84.21M
Depreciation & Amortization30K198K399K449K464K
EBITDA(9.64M)(12.43M)(31.2M)(35.67M)(77.15M)
EBITDA Margin—————
Operating Income(9.8M)(12.82M)(31.67M)(40M)(84.21M)
Operating Margin—————
Interest Income5K23K74K3.74M0
Interest Expense016K25K20K0
Other Income / Expenses131K173K45K3.86M6.6M
Income Before Tax(9.67M)(12.65M)(31.62M)(36.14M)(77.61M)
Pre-Tax Margin—————
Income Tax Expense009K6K0
Net Income(9.67M)(12.65M)(31.63M)(36.14M)(77.61M)
Net Margin—————
EPS (Basic)(0.40)(0.63)(1.19)(1.18)(2.31)
EPS (Diluted)(0.40)(0.63)(1.19)(1.18)(2.31)
Weighted Avg Shares24.1M19.98M26.59M30.54M33.54M
Weighted Avg Shares (Diluted)24.1M19.98M26.59M30.54M33.54M

Belite Bio, Inc

NASDAQ:BLTE

Intrinsic Alpha fair value

Locked

Current Price

$156.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.